Concepedia

Bingyan Wu

BW

Statistics

Publications

16

Citations

1.3K

H-Index

13

Active since

2004

Affiliations

Dana-Farber Cancer Institute(Current)

Brigham and Women's Hospital

Harvard University

Bayer (United States)

Massachusetts General Hospital

Bingyan Wu is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and pharmacology.

ORCID

Publications per year

2004–2023

16

Publications

16

Transcriptional activation of integrin β6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma

Richard C. Bates, David I. Bellovin, Courtney Brown et al. · Journal of Clinical Investigation · 2005 · 328 citations · Full text

, , +17

Transcriptional activation of integrin β6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma

Richard C. Bates, David I. Bellovin, Courtney Brown et al. · Journal of Clinical Investigation · 2005 · 308 citations · Full text

, , +17

Expanding Embedded 3D Bioprinting Capability for Engineering Complex Organs with Freeform Vascular Networks

Yongcong Fang, Yihan Guo, Bingyan Wu et al. · Advanced Materials · 2023 · 150 citations

, , +17

Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor

Roberto Bellucci, Edwin P. Alyea, Sabina Chiaretti et al. · Blood · 2005 · 101 citations · Full text

, , +14

A Phase II Trial of Irinotecan and Cisplatin in Patients with Metastatic Neuroendocrine Tumors

Matthew H. Kulke, Bingyan Wu, David P. Ryan et al. · Digestive Diseases and Sciences · 2006 · 90 citations

, , +14

1–5 of 16